Trevi Therapeutics Triumphs with Phase 2b CORAL Trial Outcomes
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical organization, has unveiled encouraging topline results from its Phase 2b CORAL trial of Haduvio. This investigational therapy is focused on treating chronic cough in patients suffering from idiopathic pulmonary fibrosis (IPF). In strikingly positive news, Haduvio achieved the primary endpoint, demonstrating statistically significant reductions in 24-hour cough frequency across all dose variants evaluated.
Clinical Findings and Statistical Significance
The trial comprised a total of 165 patients, showcasing remarkable results, notably a placebo-adjusted change of -43.3% in cough frequency at the highest dose of 108 mg BID. Statistical evidence highlights reductions of 60.2% for this group, with similar successes at lower doses—53.4% for the 54 mg BID and 47.9% for the 27 mg BID. The results from the secondary endpoints further bolstered the validity of the findings, indicating that Haduvio showed efficacy in alleviating cough severity even within the early treatment stages.
Patient Improvement Observations
Participants noticed a substantial response as early as Week 2. More impressively, 65% of recipients taking the 108 mg BID dose achieved a 50% reduction in cough frequency by Week 6. This level of improvement stands in stark contrast to only 19% within the placebo group, indicating a clear benefit for those receiving Haduvio. At the endpoint of Week 6, secondary evaluations unveiled further substantial progress, including a significant reduction in cough severity as per the cough-severity numerical rating scale (CS-NRS).
Plans for Future Development
Trevi Therapeutics is not resting on its laurels; plans are underway for an End-of-Phase 2 meeting with the FDA, with expectations to commence the Phase 3 program in the coming year. Such steps are crucial in bringing this innovative therapy closer to the patients in dire need of effective chronic cough treatment for IPF.
Expert Insights and Testimonials
Jennifer Good, President and CEO of Trevi Therapeutics, emphasized the importance of these trial results, noting the high prevalence of chronic cough in IPF patients and the absence of treatment options currently available. Collaboration with top clinical experts has driven the research forward, ensuring solutions are rooted in real patient experiences.
Safety Profile and Adverse Events
In terms of safety, Haduvio was well-received across all dosages. Discontinuation rates due to adverse effects were comparable between the Haduvio and placebo groups, suggesting a tolerable profile. The adverse events reported were consistent with previous studies, predominantly including nausea, dizziness, and headache. Importantly, serious adverse events were mostly non-fatal and reported infrequently.
About the CORAL Trial
The double-blind, randomized study evaluated multiple Haduvio doses to define its potential for chronic cough treatment among patients with IPF. The effectiveness was assessed through objective measures, ensuring conclusions drawn were scientifically robust. The encouraging outcomes provide invaluable insights for the ongoing development of Haduvio, positioning it as a leading candidate in treating this challenging condition.
About Chronic Cough and IPF
Chronic cough significantly affects the quality of life for many IPF patients, sometimes impacting up to 85% of this population. The findings from Trevi's CORAL trial present a new frontier, heralding hope for meaningful innovations in treatment strategies for those affected by this debilitating condition.
About Trevi Therapeutics, Inc.
Trevi Therapeutics is committed to developing therapies that improve patient lives, particularly in areas lacking effective treatment options. The success of Haduvio in the clinical trials reinforces the company’s mission to tackle unmet medical needs and advance healthcare solutions.
Frequently Asked Questions
What are the main findings from the CORAL trial?
The CORAL trial showed statistically significant reductions in cough frequency for all tested doses, highlighting the potential of Haduvio as a treatment for chronic cough in IPF patients.
How effective was Haduvio in the Phase 2b trial?
Haduvio led to reductions of 60.2%, 53.4%, and 47.9% in cough frequency across different dosages in comparison to placebo, establishing its effectiveness.
What are the plans for Haduvio moving forward?
The company aims to engage with the FDA for an End-of-Phase 2 meeting and commence a Phase 3 program to further evaluate Haduvio's efficacy.
What safety concerns were reported during the trial?
Adverse events were similar across treatment and placebo groups, demonstrating a favorable safety profile with no new significant risks identified.
Why is chronic cough a concern for IPF patients?
Chronic cough can severely diminish the quality of life in IPF patients, leading to both physical and psychological challenges, making effective treatment essential.
